Your Daily FinanceScope for August 03, 2025
Aries
Riding out the storm is getting old. It makes sense that you want to be in the light of day again, so go ahead and put out some exploratory feelers. Be sure that doesn't include falling right back into your old, spendthrift ways.
Taurus
When it comes to taking financial risks, you should be once burned, twice shy by now. But in every other arena, you're still a risk taker. Don't be tempted today. Remind yourself of the old saw, all that glitters is not gold.
Gemini
Don't think about business partners today. Focus on personal relationships instead. They are where the big pay off is today, and on a much deeper level than anything financial.
Cancer
Remember when your energy flowed as freely as your money? Those were the days, my friend, but don't start sobbing into your cup. It can be like that today if you learn to disconnect the two.
Leo
Romance and money are on either ends of your personal see-saw: When one goes up, the other goes down. You already know which one has hit the ground so spend the day seated on the other side. Find your cosmic purpose. Receive personalized astrological guidance with Astrology+.
Virgo
All your tension surrounding money has to be overcome if you want to get ahead in other areas. Force yourself to focus on something else for a change. Don't let yourself shrug and give it all up.
Libra
You're concerned with all things intellectual when it's your feelings that need your attention. You'll know what to spend your money on and what to take a pass on by your own visceral response to it. Pay attention to your gut.
Scorpio
Your impulses are straining against your ability to control them. Whether you pass this particular stress test will mean all the difference in the world to your financial future, so hang on for dear life.
Sagittarius
Just when you think you're not going to make it through another day, you'll get a windfall. Whether it's a twenty on the sidewalk or something more, it feels like winning the lottery.
Capricorn
Even the best interest rate on the planet won't change your situation overnight, but something else is changing with unconscious speed. Slow down and take a breath, and you might see the oasis that you've been missing.
Aquarius
Your toolbox just expanded by several sizes. It gets easier and easier to make the hard decisions. Not only can you connect the dots, you know in your heart where they lead you.
Pisces
Someone makes it their business to be your boss today. No matter what you do or say, they have a different opinion and won't hesitate to share it with you. From how you spend your money to how much is in the bank, think hard before tipping your hand. Need guidance? Your Numerology Reading is a mystic cheat-sheet to living your full potential.
Solve the daily Crossword
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America
MONTREAL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has expanded its existing relationship and amended its agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), for the exclusive rights to distribute retifanlimab (sold as ZYNYZ® in the United States and Europe) and axatilimab (sold as NIKTIMVO™ in the United States) in Latin America. Under the terms of the amended agreement Incyte will be responsible for the development, manufacture and supply to Knight of retifanlimab and axatilimab, and Knight will be responsible for seeking the necessary regulatory approvals and distributing both medicines in Latin America. Knight and Incyte had entered into an exclusive supply and distribution agreement for MINVUVI® (tafasitamab) and PEMAZYRE® (pemigatinib) in Latin America in September 2021. Retifanlimab is approved in the United States and Europe for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer.1 Based on epidemiological data from two Brazilian registries, there are an estimated 550 – 1,250 new cases of MCC each year across Brazil, Mexico, Colombia and Argentina.2 Retifanlimab is also approved by the U.S. Food and Drug Administration (FDA) in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC).1 In addition, the FDA approved retifanlimab as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.1 While epidemiological data for SCAC in LATAM is limited, there are approximately 2,700 – 4,000 new cases of SCAC each year in Brazil, Mexico, Colombia and Argentina.3 Axatilimab received FDA approval in August 2024 for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.4 Chronic GVHD is a serious complication of allogeneic stem cell transplantation in which the donor's immune cells attack the recipient's tissues, potentially affecting multiple organs such as the skin, liver, lungs, and gastrointestinal tract. There are approximately 1400 – 1800 reported allogeneic transplants in Brazil every year.5 'We are thrilled to expand our partnership with Incyte and for the opportunity to bring two innovative biologic products to the LATAM region,' said Samira Sakhia, President and CEO of Knight Therapeutics. 'These therapies are highly complementary to our existing portfolio and will significantly strengthen our presence in oncology and hematology, reinforcing our commitment to delivering transformative treatments to patients across Latin America.' 'As a partner, Knight, has an extensive track record of successful collaborations as well as strong distribution capabilities in Latin America,' said Lee Heeson, Executive Vice President and Head of Incyte International. 'We look forward to continuing to work together and to expanding our existing partnership for tafasitamab and pemigatinib to include retifanlimab and axatilimab so that eligible patients in the region can access our innovative medicines.' About Retifanlimab ZYNYZ® (retifanlimab-dlwr) is a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) and as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression or intolerance to platinum-based chemotherapy in the U.S.1 ZYNYZ® is also indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in the U.S. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.1 ZYNYZ® is marketed by Incyte in the United States. In 2017, Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc. for global rights to retifanlimab. ZYNYZ® is a registered trademark of Incyte. About Axatilimab NIKTIMVO™ (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg .4 In 2016, Syndax licensed exclusive worldwide rights to develop and commercialize axatilimab from UCB. In September 2021, Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement for axatilimab in cGVHD and any future indications. Axatilimab is being studied in frontline combination trials in chronic GVHD; a Phase 2 combination trial with ruxolitinib (NCT06388564) and a Phase 3 combination trial with steroids which are expected to initiate by year end. Axatilimab is also being studied in an ongoing Phase 2 trial in patients with idiopathic pulmonary fibrosis (NCT06132256). NIKTIMVO™ is a trademark of Incyte. All other trademarks are the property of their respective owners. References Incyte Corporation. ZYNYZ (retifanlimab-dlwr) injection, for intravenous use: Full prescribing information. Retrieved July 24, 2025, from Melo, Andreia C de, and Luiz C Santos Thuler. 'Trends in the Incidence and Morbidity of Merkel Cell Carcinoma in Brazil.' Future Oncology 17, no. 22 (May 7, 2021): 2857–65. Mignozzi, Silvia, Claudia Santucci, Matteo Malvezzi, Fabio Levi, Carlo La Vecchia, and Eva Negri. 'Global Trends in Anal Cancer Incidence and Mortality.' European Journal of Cancer Prevention 33, no. 2 (November 27, 2023): 77–86. Incyte Corporation. NIKTIMVO (axatilimab-csfr) injection, for intravenous use: Full prescribing information. Retrieved July 24, 2025, from Associação Brasileira De Transplante De Órgãos. 'Registro Brasileiro de Transplantes.'XXV No. 3. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at or Forward-Looking Statements This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2024, as filed on Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law. Investor Contact: Knight Therapeutics Inc. Samira Sakhia Arvind Utchanah President & Chief Executive Officer Chief Financial Officer T: 514.484.4483 T. +598.2626.2344 F: 514.481.4116 Email: IR@ Email: IR@ Website: Website:
Bloomberg
an hour ago
- Bloomberg
Wall Street Rallies as S&P 500 Jumps 1.5%
Comprehensive cross-platform coverage of the U.S. market close on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Scarlet Fu, Carol Massar and Matt Miller. (Source: Bloomberg)
Yahoo
2 hours ago
- Yahoo
Banco Macro S.A. (BMA): A Bull Case Theory
We came across a bullish thesis on Banco Macro S.A. on Jeremie Boyer's Substack. In this article, we will summarize the bulls' thesis on BMA. Banco Macro S.A.'s share was trading at $71.99 as of July 30th. BMA's trailing P/E was 3.82 according to Yahoo Finance. A trader on the floor of a bank's trading room, surrounded by sophisticated electronic equipment. Banco Macro (BMA) appears poised for a valuation re-rating as profitability normalizes, supported by accelerating loan growth, recent share buybacks, and a strong brand-driven retail presence. The bank holds a dominant 74% branch share in Argentina's high-growth interior provinces, positioning it to benefit disproportionately from any rebound in real credit demand as interest rates fall. This provincial SME lending footprint is a structural advantage, particularly in a rising-rate or recovery environment. With a Common Equity Tier 1 (CET1) ratio above 25%, BMA enjoys significant capital flexibility, enabling it to simultaneously fund loan expansion and conduct additional share repurchases without compromising regulatory buffers. Its brand equity is also surging—BMA was ranked #4 in the Brand Finance Argentina 10 (2025) and named the fastest-growing brand in the country, with a 114% year-over-year increase in brand value to $622 million. This visibility strengthens deposit stickiness and customer loyalty, both of which are critical in a volatile macro environment. Earnings also exhibit high sensitivity to net interest margin (NIM) recovery; every 100 basis point increase in NIM translates to approximately $0.25 in incremental EPS per ADR, providing substantial operating leverage to any normalization in monetary conditions. The brand's reputational strength places it firmly in the 'A-Tier' of Argentine banks, correlating with better deposit stability, pricing power, and competitive resilience. Taken together, these dynamics support a base-case price target of $95–100 per ADR as earnings normalize. With multiple embedded levers for upside, BMA offers a compelling risk-reward profile for both equity and credit investors. Previously, we covered a on Northeast Bank (NBN) by Rock & Turner in May 2025, which highlighted the bank's opportunistic loan acquisitions, exceptional credit quality, and disciplined capital deployment. The company's stock price has appreciated by approximately 17.77% since our coverage. This is because the bank's differentiated model began reflecting in valuation. The thesis still stands as NBN's profitability remains scalable. Jeremie Boyer shares a similar view but emphasizes provincial scale and NIM-driven earnings torque in Banco Macro (BMA). Banco Macro S.A. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 16 hedge fund portfolios held BMA at the end of the first quarter which was 18 in the previous quarter. While we acknowledge the potential of BMA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Sign in to access your portfolio
